ArticleFrontiers in oncology2026
A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the diagnostic value of multimodal MRI by comprising quantitative mapping, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced MRI (DCE-MRI) in differentiating triple-negative breast cancer (TNBC) from non-TNBC, and to investigate the correlation between significant quantitative mapping parameters and the Ki-67 proliferation index. Methods: This prospective study enrolled 120 patients with invasive breast cancer (30 TNBC and 90 non-TNBC) who underwent preoperative quantitative mapping, DWI, and DCE-MRI. DCE-MRI parameters (RE, ME, MRE, T0, TTP, WI, WO, BOE), DWI metrics (ADCmin, ADCmean, rADCmin, rADCmean), and quantitative mapping parameters (Native T1, Enhanced T1, ΔT1, ΔT1%, T2) were compared between groups. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC) for both individual significant parameters and a combined predictive model. Pearson' s correlation coefficient was used to analyze the relationship between quantitative mapping parameters and the Ki-67 index. Results: Compared to the non-TNBC group, TNBC lesions exhibited significantly lower RE, ME, WI, WO, and ΔT1% ( Conclusion: Parameters including RE, ME, WI, WO, Enhanced T1, ΔT1%, and T2 serve as valuable imaging biomarkers for the preoperative identification of TNBC. Integrating quantitative mapping with DCE-MRI significantly enhances diagnostic performance, offering a robust approach for differentiating TNBC from non-TNBC subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.